Merck CEO Downplays Cost Concerns Over Intismeran Cancer Vaccine
Merck CEO Rob Davis says the complex manufacturing of the personalized cancer vaccine Intismeran should not limit patient access, according to Stocktwits.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Merck CEO Rob Davis said the company does not see cost as a barrier to patient access to the drug. He said Merck expects competitive production costs, even though making the vaccine is complicated. His remarks came in a CNBC interview after Citi analysts questioned whether the clinical benefits justify the cost and complexity of production.
The vaccine is being developed jointly with Moderna using mRNA technology and is being tested alongside Keytruda. Davis said it takes about six weeks to go from analyzing a patient's tumor to producing the finished vaccine. Phase 3 trial data show the combination cuts the risk of melanoma recurrence or death by 42%, rising to 58% after six months. The companies plan to file for regulatory approval before the end of 2026 and expect possible approval in 2027. Information is according to Stocktwits.
MRNA shares fell more than 17% on Thursday after the data, leaked ahead of the ESMO presentation, fell short of investor expectations.
why it matters
Two points matter for the market: the timing of regulatory review and whether Merck can scale production of the personalized vaccine. The sharp drop in MRNA shares shows investors expected stronger results, so further data on the drug will be closely watched.
market impact
MRK, MRNA: doubts about vaccine economics and approval timing weigh on biotech valuations
tags
instruments
sources
- Merck CEO Plays Down Cost Concerns Over Intismeran — ‘We Don't See Cost As A Limit To Access’ — Stocktwits, 23 October 2026 at 15:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗